Compare Citius Pharmaceuticals Inc (CTXR) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs BlackRock TCP Capital Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while BlackRock TCP Capital Corp trades at $3.28 (market cap $265.55M). The key difference: BlackRock TCP Capital Corp is far larger — about 18.1× Citius Pharmaceuticals Inc's market cap, and BlackRock TCP Capital Corp pays a 26.54% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TCPC | |
|---|---|---|
Market Cap | $14.64M | $265.55M |
Sector | Health | Financials |
52-Week High | $1.82 | $7.84 |
52-Week Low | $0.53 | $3.14 |
Enterprise Value | $10.86M | — |
Dividend Yield | — | 26.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
TCPC trades at $3.15, down 3.37% today, with a bearish technical signal and negative revenue trends. The company reported a net loss of $88.93M in 2025 despite a 112% net income margin, driven by negative revenue. Analyst consensus shows mixed sentiment with 31% buy ratings, while recent news includes a Zacks upgrade and upcoming Q2 earnings on August 6, 2026.
The outlook remains challenging with persistent negative revenue and profitability issues. Investment opportunities include the low P/B ratio of 0.47 and dividend yield, but risks include ongoing losses, shareholder litigation, and bearish technical indicators. The stock faces significant fundamental headwinds despite some analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
